Figure 3.

Paricalcitol inhibits RANTES/CCL5 and TNF-α but not MCP-1/CCL2 mRNA expression in obstructive nephropathy. (A and B) RT-PCR results showed that paricalcitol suppressed renal RANTES and TNF-α mRNA expression at 7 d (A) and 14 d (B), respectively, after UUO in a dosage-dependent manner; however, no significant difference in MCP-1 mRNA abundance was observed after paricalcitol treatment, compared with vehicle controls. Numbers (1, 2, and 3) denote each individual animal in a given group. Dosages of paricalcitol were 0.3 and 0.1 μg/kg body wt, respectively. (C and D) Renal mRNA levels of RANTES, TNF-α, and MCP-1 in various groups. Relative mRNA levels at 7 d (C) and 14 d (D) after UUO were calculated and expressed as fold induction over sham controls (value = 1.0) after normalization with β-actin. Data are means ± SEM of five animals per group. *P < 0.01 versus sham control; †P < 0.01 versus vehicle.